Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NG\vb3RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{e0VlAuOC53IN88US=> NUPTZotQOjRiaB?= MoHF[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NULUXVk4OjV4NkO3Olk>
HepG2-HBV1.1 MmHQRZBweHSxc3nzJGF{e2G7 MUiwMVAvPSEQvF2= M4e3T|I1KGh? MVzpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MUCyOVY3Ozd4OR?=
HepG2.2.15 NW\KXZFoTnWwY4Tpc44hSXO|YYm= MU[wMlEh|ryP NGXYOIkzPCCq NGLMbW1xem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44> MWeyOVY3Ozd4OR?=
HepG2-HBV1.1 NGfE[HVHfW6ldHnvckBCe3OjeR?= M4HYc|AvOSEQvF2= M3nlPFI1KGh? MYfwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= M4H4b|I2PjZ|N{[5
HepG2-HBV1.1 MXTGeY5kfGmxbjDBd5NigQ>? NWHPUo57OC5zIN88US=> M4\uN|Q5KGh? M4S5c5Bzd22xdHXzJINmdGxiZYjjdoV1cW:wIH;mJIhmeGG2aYTpd{BDKH[rcoXzJI52[2ynb3PhdJNq\HNiaX7zeIVi\CCxZjDo[ZBifGm2aYOgRkB3cXK3czDEZY5mKHCjcoTpZ4xmew>? NGDXXZQzPTZ4M{e2PS=>
HepG2-HBV1.1 NFXkSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGwMlEh|ryP MmHyNU02KGR? Ml73bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= NEfJfnozPTZ4M{e2PS=>
HepG2-HBV1.1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnKbXoxNjFizszN M{PIU|EuPSCm MoX1bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= MYeyOVY3Ozd4OR?=
HepG2-HBV1.1 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHX[JExNjFizszN MWixNk04OiCq M{PzTolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> NVPpfZZxOjV4NkO3Olk>
HepG2-HBV1.1 NIPIR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrqNHl[OC5zIN88US=> NITVdHoyOi15MjDo NIeyTXpqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> NYfYZolHOjV4NkO3Olk>
Raji MYXGeY5kfGmxbjDBd5NigQ>? NUXSO5VzOC53wrFOwG0> Moi5O|IhcA>? M4LhboFjd2yrc3jld{BifXSxcHjh[5nDqA>? MW[yOVQ1PjN5Nx?=
SK-MEL-28  MVPGeY5kfGmxbjDBd5NigQ>? MnO2N|Ahdk1? NHWzcpQ3KGh? NFSyUHZqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= MljNNlU{OTNyMUC=
H157 M33RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\STWM2OD1zLkCzJOKyKDBwMESgcYl2Ok1? M2m0V|I2OjV5OUGx
Jurkat NVT3UVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTOd3YyNTNibl2= M1L1ZVQ5yqCq MWXEUXNQ MnjF[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> NF3ycnAzPTF3NkG0Oi=>
CEM MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LtblEuOyCwTR?= M1PqZVQ5yqCq NH6zXlhFVVOR NYiybopu\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NYS4T4F3OjVzNU[xOFY>
P12 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjaXVhWOS1|IH7N MnfnOFjDqGh? NGWzfpFFVVOR MWjk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 M{fhWFI2OTV4MUS2
KB M3izXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPBTWM2OD1yLkCwOFkhyrFiMD6wNFAyKM7:TR?= NWXrTXFrOjVyNUi1NlY>
KBv200 (ABCB1) M1jtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;NTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= Mom1NlUxPTh3Mk[=
SUDHL6  NUXXbHZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKx5qCK|ryP MWG0PE84OiCq NW\qbnlscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M2\KWVI1QTZzNkC0
SUDHL6  Ml3mSpVv[3Srb36gRZN{[Xl? MlPBNgKBkc7:TR?= NYDsd2l3PzJiaB?= NH\V[5RqdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D NInEXo8zPDl4MU[wOC=>
HCT-116 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnHTVUxRTVibl2= MoXkNlQ6Ojd6NUe=
SKNBe2C M3PUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN{LklCtVQvOCCwTR?= NH3hXngzPDl{MUmyNC=>
IGNR91 NVXYUpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTsZ2NKSzVyPUK0MlPDuTFwNzDuUS=> MnXQNlQ6OjF7MkC=
SKNAS M3:wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7UTWM2OD1zLkZCtVAvOiCwTR?= MViyOFkzOTl{MB?=
LAN1 M1XUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmmxTWM2OD1{LkRCtVAvOiCwTR?= M{S4dFI1QTJzOUKw
SHSY5Y M1fnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LRR2lEPTB;OD6yxtExNjZibl2= MkKyNlQ6OjF7MkC=
A549-WT NYjHSGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1? M37vTFI1QDV6OEK3
A549-R MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? MkDhNlQ5PTh6Mke=
MCF-7-WT M4\VZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;XNFVKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2= NXHKVoU3OjR6NUi4Nlc>
MCF-7-R MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwNUO5JOKyKDBwMUS0JEBvVQ>? M1zmUlI1QDV6OEK3
A549-R Mly0R5l1d3SxeHnjbZR6KEG|c3H5 M3H5dGlEPTB;MUKuNVc5KMLzIECuN|M{KG6P MVuyOFg2QDh{Nx?=
MCF-7-R NXrubmlyS3m2b4TvfIlkcXS7IFHzd4F6 M4rBeWlEPTB;NT61N|khyrFiMD6xOFQhdk1? NEfxfnYzPDh3OEiyOy=>
SW620 NWL4No1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\ITWM2OD15LkiwJOKyKDBwMEigcm0> NVXzNm41OjR5Mk[3N|k>
SW620/AD300 NUH6[ZlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfY[IdKSzVyPUmwPU43OCEEsTC4MlkyKG6P MXiyOFczPjd|OR?=
HEK293/pcDNA3.1 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLOVGRKSzVyPUGuOFUhyrFiMD6yNEBvVQ>? NU\ROFZFOjR5Mk[3N|k>
HEK293/ABCC1 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\QTWM2OD1zOT6yPUDDuSB{LkC4JI5O MYeyOFczPjd|OR?=
TCC M4rwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjsfI8yOjRiaB?= MlHkTWM2OD15MDDuUS=> NEjzUHAzPDdzNkm0OC=>
TCC NGfPeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qOFghcA>? MofuTWM2OD13MDDuUS=> MUOyOFcyPjl2NB?=
HepG2/ADM NEHWb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XaOGlEPTB;Mj63PFY{yrFyLkKzO|Eh|ryP MVGyOFcxPDV3Nh?=
HepG2 M1fkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInDdXpKSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?= MoflNlQ4ODR3NU[=
MCF-7/ADR NI\DXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjH[mRSUUN3ME20MlQ5OjcEsUCuNlA4OCEQvF2= M3nKflI1PzB2NUW2
MCF-7 NUHTWpgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXtTWM2OD1yLkCxOVnDuTBwMEC2NkDPxE1? MYKyOFcxPDV3Nh?=
A-172  NETkVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[yNE4yyqEQvF2= NWHDRmxHOjRxN{KgbC=> MU\pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 MYWyOFU{ODJ|NR?=
U-251MG NVSwPIg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTBNE4yyqEQvF2= MmXkNlQwPzJiaB?= NILpbVhqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 M2eyN|I1PTNyMkO1
DLD-1 M{fMR2Z2dmO2aX;uJGF{e2G7 M1S4eVExOCCwTR?= MVO0PEBp MkK5dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh MVOyOFQxOzR3Mx?=
CCD18Co MWfGeY5kfGmxbjDBd5NigQ>? M4jPWVExOCCwTR?= NEP0WYk1QCCq NFvhRYhxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? M1;PdFI1PDB|NEWz
DLD-1 NILSW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOwMVExODBibl2= NWrWNpZlPDhiaB?= Mom0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NUDVXHNWOjR2MEO0OVM>
CCD18Co M1jBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX64do1ZOC1zMECwJI5O M3jueFQ5KGh? NUW1c45IcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MX:yOFQxOzR3Mx?=
HepG2 NV6wZ|J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlriNlQhcA>? NGrTR|dKSzVyPUWyMlXjiIoQvF2= MnrjNlQ{PDF4OEi=
HEK293/pcDNA3.1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEC0xtExNjByMEOg{txO MmjDNlQzQDR5OEO=
HEK293/MRP1 NIHwRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm4UFFbUUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?= NXP0e2ttOjR{OES3PFM>
Ramos NUfMb3JZSXCxcITvd4l{KEG|c3H5 MXqy5qCK|ryP MUW0PEBp NFHEc4JqdmS3Y3XzJFM1NjZnwsGxMlkzLSCjcH;weI9{cXN? M3rzOFI1OjV4NEmx
NCI-H1299/pcDNA3 NWfYRYdXS2WubDDWbYFjcWyrdImgRZN{[Xl? NGL6e24xNTJyIH7N MVm5OkBp M2r3e4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUOyOFE4PzBzMh?=
H1299/ICAM-3 MnvFR4VtdCCYaXHibYxqfHliQYPzZZk> MoXENE0zOCCwTR?= MoS4PVYhcA>? NWDIclhIcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NHTEVpEzPDF5N{CxNi=>
NCI-H1299/pcDNA3 MXzGeY5kfGmxbjDBd5NigQ>? MnnNNU82NzFyL{KwxsBvVQ>? NXmyZ2E3QTZiaB?= M3vC[4lv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> MljMNlQyPzdyMUK=
H1299/ICAM-3 MXXGeY5kfGmxbjDBd5NigQ>? MUKxM|UwOTBxMkFCpI5O M4HvOFk3KGh? MojvbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> NEK5T2szPDF5N{CxNi=>
W1 M3PzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[zWIlzUUN3ME2wMlAxOzJizszN NFjJNmQzPDF2MEG3Oi=>
W1VR M{\FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzGOlRKSzVyPUCuNFU3KM7:TR?= NEjX[4EzPDF2MEG3Oi=>
K562 M4TLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? NWnIbXBVOjRzM{W5N|c>
K562/ADR NEDKOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLmTWM2OD1|LkK2NUDDuSByLkSxNkDPxE1? NF\DVVkzPDF|NUmzOy=>
K562 NWXhcGtxSXCxcITvd4l{KEG|c3H5 NEjKOnAxNjNizszN M3rJeFI1KGh? MWnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M3HrdVI1OTN3OUO3
K562/ADR Mom1RZBweHSxc3nzJGF{e2G7 M{[4[FMh|ryP NFjKXpYzPCCq MnnsbY5lfWOnczDhdI9xfG:|aYO= NH\2OIQzPDF|NUmzOy=>
A549 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TLc2lEPTB;MD6xNEDDuSByLkCzJO69VQ>? M{j1W|I{QTdzMEe1
K562 NUHvOYZFS2WubDDWbYFjcWyrdImgRZN{[Xl? NYG3XZBkOy55NfMAl|YxyqCwTR?= NUT0e2tzPzMEoHlCpC=> NYe2[I1RcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MmrmNlM5Pzd{MkO=
lucena MkniR4VtdCCYaXHibYxqfHliQYPzZZk> NV7ZU3dWOy55NfMAl|YxyqCwTR?= NHjLVow4OsLiaNMg NEfCVYJvdyCnZn\lZ5Q> NHjkb4UzOzh5N{KyNy=>
FEPS NWHifohPS2WubDDWbYFjcWyrdImgRZN{[Xl? NFvpRlM{Njd34pETOlDDqG6P M2jy[VczyqCqwrC= MYruc{Bm\m[nY4S= MXWyN|g4PzJ{Mx?=
A2780 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLZTphjUUN3ME2zMlUhdU1? MWWyN|gzQTJyMx?=
ACHN MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\OUmlEPTB:MD6xJI1O Moj2NlM5Ojl{MEO=
U-937 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K0dmlEPTB:M{Sgcm0> M2\IfVI{QDJ7MkCz
Jurkat NFzXcHpCeG:ydH;zbZMhSXO|YYm= MnjKOeKh|rypL33sxsA> NG\C[oMzPCCq M1jFfYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? M{DlflI{QDFyNEC5
Jurkat NHHRVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vEUFXDqM7:Zz;tcOKh MmPvNlQhcA>? NITZZ4xienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W= M1foWVI{QDFyNEC5
Hep-2 NGqzUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvYPYhuUUN3ME2wMlA1yrFyLkCxJO69VQ>? MX[yN|c5ODR{NB?=
Hep-2/v MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwONMxNE4zOCEQvF2= NEjOTVczOzd6MESyOC=>
SGC-7901 M3;hZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nGW|AuOTBizsznM41t MYmyOE81QC95MjDo M{frZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MV6yN|c1OzV5Mh?=
SGC-7901/VCR NVf5R2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\MRVAuOTBizsznM41t MUOyOE81QC95MjDo MnfhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M37PSVI{PzR|NUey
SGC-7901 MYTBdI9xfG:|aYOgRZN{[Xl? M1PxPYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NG\FZXUzOzd2M{W3Ni=>
SGC-7901/VCR MWTBdI9xfG:|aYOgRZN{[Xl? NUPzT2lycW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M2rsS|I{PzR|NUey
KB-3-1 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDkZYJbUUN3ME2xMlY3KMLzIECuNVYzKM7:TR?= NHzHTYQzOzZ5M{S0OS=>
KB-C2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrPTWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?= MX[yN|Y4OzR2NR?=
KB-3-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jCNmlEPTB;MT6yOkDDuSByLkCyO{DPxE1? MV:yN|Y4OzR2NR?=
KB-V1 NV75fI96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PZc2lEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP Mn;UNlM3PzN2NEW=
HEK293/pcDNA3.1 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;uc2lEPTB;MkSuNUDDuSByLkKwOEDPxE1? MXOyN|Y4OzR2NR?=
HEK293/ABCB1 NGj6[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTVTWM2OD1|NUGyMlghyrFiM{e4MlM6OSEQvF2= MVqyN|Y4OzR2NR?=
A549/EGFP  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILsXWUxNjBzLUGwNFAh|ryP M33yemlEPTB;OE[uO{DDuSB{OT6xJO69VQ>? NFfJV3AzOzZ|NEK4Ni=>
A549/Slug MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMlAyNTFyMECg{txO Ml3tTWM2OD17LkegxtEhOy5zIN88US=> MYKyN|Y{PDJ6Mh?=
JFCR39  Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfROJhLOSEEtV2= NYDZRXJkOjRiaB?= MUfEUXNQ NEfTNYJu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| NWPQ[JB7OjN3OUiyO|Y>
A549 MoG4SpVv[3Srb36gRZN{[Xl? M2q4elExOCCwTR?= MWGxOkBp MUjEUXNQ NFvvcoht\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| M1LVUVI{PTl6Mke2
SGC7901 NGLBVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PhWmlEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> NEXmb2ozOzV4NES4Ni=>
SGC7901/LV-NC NHfNcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7GSXNJUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? Mk\TNlM2PjR2OEK=
SGC7901/LV-SGO1 NVXHenNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG1eHFKSzVyPUSuN|bjiIoEsfMAjVAvOzdizsznM41t M3;PflI{PTZ2NEiy
SGC7901/VCR NFTucoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HLfWlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t M1Hy[VI{PTZ2NEiy
SGC7901/VCR-NC NFP1RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGwb3lKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>? Mn\XNlM2PjR2OEK=
SGC7901/VCR-si-SGO1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jDfmlEPTB;Nj6xPQKBkcLz4pEJNU4xOyEQvHevcYw> MorRNlM2PjR2OEK=
SGC7901/ADR M1f6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwOEZihKnDueLCiUCuOlQh|rypL33s NV7H[WlKOjN3NkS0PFI>
SGC7901/ADR-NC Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q1SGlEPTB;OD65N-KBkcLz4pEJNE43QCEQvHevcYw> NXfYfWp[OjN3NkS0PFI>
SGC7901/ADR-si-SGO1 NW\KdYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNwNEdihKnDueLCiUCuNlkh|rypL33s MkTjNlM2PjR2OEK=
SH-SY5Y  NYG5e5oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jXV|AvODBzLUGwJO69VQ>? MmrPNlQhcA>? NU\SdWRYUUN3ME2wMlEyO8LzMD6wNVIh|ryP NUP0fY1FOjNzMkmwOlU>
SH-SY5Y  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULLdWxpOC5yMEGtNVAh|ryP MX[0PEBp NXrXcWJCUUN3ME2wMlA4QMLzMD6wNFkh|ryP MUiyN|EzQTB4NR?=
SH-SY5Y  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMlAxOS1zMDFOwG0> MYS3NkBp MVTJR|UxRTBwMEWxxtExNjByODFOwG0> NIr4VlUzOzF{OUC2OS=>
SH-SY5Y M1H0XWFxd3C2b4Ppd{BCe3OjeR?= MkPVNE4yKM7:TR?= M{XTNVAuOjRiaB?= NV;tWmpFcW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> MmXlNlMyOjlyNkW=
SH-SY5Y MlTCRZBweHSxc3nzJGF{e2G7 MVqwMlEh|ryP MlL0NE0zPCCq NVXm[nFzcW6mdXPld{BucXSxdHnjJIFzemW|dNMg NGX1U4IzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID